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Objective: To determine the incidence, risk factors, and impact on outcome of prolonged empirical antifungal
treatment in ICU patients.
Methods: Retrospective observational study performed during a one-year period. Patients who stayed in the
ICU >48 h, and received empirical antifungal treatment were included. Patients with confirmed invasive fungal
disease were excluded. Prolonged antifungal treatment was defined as percentage of days in the ICU with
antifungals > median percentage in the whole cohort of patients.
Results: Among the 560 patients hospitalized for >48 h, 153 (27%) patients received empirical antifungal treatment
and were included in this study. Fluconazole was the most frequently used antifungal (46% of study patients).
Median length of ICU stay was 19 days (IQR 8, 34), median duration of antifungal treatment was 8 days (IQR 3, 16),
and median percentage of days in the ICU with antifungals was 48% (IQR 25, 80). Seventy-seven patients (50%)
received prolonged empirical antifungal treatment. Chemotherapy (OR [95% CI] 2.6 [1.07-6.69], p = 0.034), and
suspected infection at ICU admission (3.1 [1.05-9.48], p = 0.041) were independently associated with prolonged
empirical antifungal treatment.
Duration of mechanical ventilation and ICU stay were significantly shorter in patients with prolonged empirical
antifungal treatment compared with those with no prolonged empirical antifungal treatment. However, ICU
mortality was similar in the two groups (46 versus 52%, p = 0.62).
Conclusion: Empirical antifungal treatment was prescribed in a large proportion of study patients. Chemotherapy,
and suspicion of infection at ICU admission are independently associated with prolonged empirical antifungal
treatment.
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Invasive fungal disease is common in critically ill patients.
Based on the results of the large international EPIC II
study [1], fungi are responsible for 19.4% of all docu-
mented infections in the intensive care unit (ICU). These
patients have several risk factors for fungal infection, in-
cluding invasive procedures, prolonged antimicrobial
treatment, fungal colonization, abdominal surgery, paren-
tal nutrition, and immunosuppression [2,3]. Substantial
morbidity and mortality were reported in ICU patients* Correspondence: s-nseir@chru-lille.fr
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unless otherwise stated.with confirmed invasive fungal disease. Prompt appropri-
ate antifungal treatment is a key factor in the prognosis of
ICU patients suffering from invasive fungal disease [4].
Therefore, empirical antifungal treatment is frequently
prescribed to these patients when fungal infection is sus-
pected. However, the diagnosis of invasive fungal disease
is still extremely difficult in this population, because of the
absence of an accurate non invasive diagnostic method
[5]. In addition, no clear evidence-based recommenda-
tions are available on how and when to de-escalate
antifungal treatment. Therefore, empirical antifungal
treatment is frequently used for a long period of time in
the ICU. Prolonged antifungal treatment is responsible ford. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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resistance.
To our knowledge, few data are available on prolonged
empirical antifungal treatment. A recent study was con-
ducted to determine the incidence of systemic antifungal
use in critically ill patients without invasive fungal disease
[6]. However, no information was provided on prolonged
empirical antifungal treatment incidence. In addition, risk
factors for prolonged duration of antifungal treatment and
its impact on outcome are unknown. Further, prolonged
antifungal use is a well-known risk factor for emergence
of antifungal resistance [7]. Identifying the incidence, risk
factors and impact on outcome of prolonged empirical an-
tifungal treatment might be helpful for future studies aim-
ing at reducing the duration of this treatment. Therefore,
we conducted this retrospective observational study to de-
termine, incidence, risk factors, and impact on outcome of
prolonged antifungal treatment.
Patients and methods
This retrospective study was conducted in a 30-bed
medical and surgical university ICU during a one-year
period (from January 2011 to January 2012). Informed
consent was not required by the local IRB because of the
retrospective non interventional design of the study.
All adult patients hospitalized in the ICU for more
than 48 hours who received empirical antifungal treat-
ment were eligible for this study. Patients with con-
firmed invasive fungal disease were excluded.
Study patients
In patients with suspected invasive fungal infection, blood
cultures were systematically performed before empirical
antifungal treatment [8]. In addition, other microbiological
specimens were performed based on patient’s clinical sta-
tus. Candida colonization index was not routinely per-
formed. Antifungal treatment was based on written local
guidelines. Briefly, fluconazole, or caspofungin were rec-
ommended as initial therapy for suspected invasive can-
didiasis in non neutropenic patients. Lipid formulation of
amphotericin B was recommended as alternative if there
is intolerance to other antifungals. In neutropenic patients,
lipid formulation of amphotericin B, caspofungin, or vori-
conazole were recommended for empirical treatment of
suspected candidiasis. No prophylactic antifungal treat-
ment was used during the study period.
Definitions
Prolonged antifungal treatment was defined as percentage
of days in the ICU with antifungals > median percentage
in the whole cohort of patients. Recent hospitalization was
defined as any hospitalization for >48 h during the
3 months preceding ICU admission. Immunosuppression
was defined as neutropenia (<500/μL), chemotherapyduring the last three months, or long-term corticosteroids
use. Prior antimicrobial, and antifungal treatment, was de-
fined as any treatment by these agents during the 3 months
preceding ICU admission.
Data collection
The following data were collected at ICU admission:
age, gender, simplified acute physiology score II, logistic
organ dysfunction score, location before ICU admission
(other wards, other ICUs, home), recent hospitalization,
category of admission (medical, surgical, trauma), co-
morbidities (diabetes mellitus, chronic heart failure,
chronic obstructive pulmonary disease, cirrhosis, chronic
dialysis, immunosuppression), McCabe score, causes for
ICU admission, suspected infection at ICU admission,
prior antibiotic treatment, and prior antifungal treat-
ment. In addition, the following data were collected dur-
ing ICU stay: number of sites colonized with fungi,
antibiotic treatment, mechanical ventilation, central ven-
ous catheter, arterial catheter, dialysis, duration of ICU
stay, duration of antifungal treatment, parental nutrition,
and ICU mortality.
Statistical analysis
The percentage of days in the ICU with antifungal treat-
ment was calculated for each patient, as well as median
(25th, 75th IQR) percentage in the study cohort. Patients
were classified as having a prolonged duration of anti-
fungal treatment if they had a percentage of days in the
ICU with antifungal treatment > median percentage of
days in the ICU with antifungals, or as not having a pro-
longed duration of antifungal treatment if they had a
percentage of days in the ICU with antifungal treat-
ment ≤median percentage of days in the ICU with
antifungals.
Statistical analysis was performed using SPSS software
(version 15.0, SPSS, Chicago, IL). Results of qualitative
variables are presented as numbers (percentage). Distri-
bution of quantitative variables was tested. Normally and
non normally distributed variables are expressed as
mean ± SD and median (25th, 75th IQR); respectively.
To determine risk factors for prolonged empirical anti-
fungal treatment, patients with prolonged empirical anti-
fungal treatment were compared with patients with no
prolonged empirical antifungal treatment by univariate
analysis. Qualitative variables were compared using chi2
or Fischer’s exact test, as appropriate. Quantitative vari-
ables were compared using Student’s t test or Mann
Whitney U test, as appropriate. Multivariate analysis was
used to determine risk factors independently associated
with prolonged empirical antifungal treatment. All data
from univariate analysis with p values <0.1 were incor-
porated in the multivariate conditional logistic regres-
sion analysis. Backward stepwise was used in the logistic
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to determine the model goodness-of-fit.
Results
Among the 560 patients hospitalized >48 h during the
study period, 161 (28%) patients were eligible for this
study, and 153 (27%) patients were included. Eight (1.4%)
patients were excluded for confirmed invasive fungal dis-
ease (8 candidemia) (Figure 1). Fluconazole was the most
frequently used antifungal (46% of study patients),
followed by caspofungin (39%), voriconazole (12%), and li-
posomal amphotericin B (3%). Four patients (2%) received
more than one antifungal during their ICU stay.
In study patients, median length of ICU stay was
19 days (IQR 8, 34), median duration of antifungal treat-
ment was 8 days (IQR 3, 16), and median percentage of
days in the ICU with antifungals was 48% (IQR 25, 80).
Seventy-seven patients (50%) received prolonged empir-
ical antifungal treatment. Patient characteristics are pre-
sented in Tables 1, and 2. 35 patients (22% of study
patients, and 6% of the whole cohort) received empirical
antifungal treatment before ICU admission.
Factors associated with prolonged empirical antifungal
treatment by univariate analysis
At ICU admission, chemotherapy, corticosteroid use,
hospital-acquired pneumonia, suspected infection, and
prior antifungal treatment were significantly more frequent
in patients with prolonged antifungal treatment compared
with those with no prolonged antifungal treatment.
During ICU stay, percentage of patients with arterial
catheter, duration of central venous catheter use, and ar-
terial catheter use were significantly lower in patients
with prolonged antifungal treatment compared with
those with no prolonged antifungal treatment.
Factors associated with prolonged empirical antifungal
treatment by multivariate analysis
Chemotherapy (OR [95% CI] 2.6 [1.07-6.69], p = 0.034),
and infection at ICU admission (3.1 [1.05-9.48], p =
0.041) were independently associated with prolongedPatients hospitalized >48h
n=560






Figure 1 Study flowchart.empirical antifungal treatment. Hosmer-Lemeshow test
was not significant (p 0.579), confirming the model
goodness-of-fit.
Impact of prolonged empirical antifungal treatment on
outcome
Duration of mechanical ventilation (12.5 [4,9] versus 20
d (0, 36), p = 0,007) and ICU stay (18 [5-28] versus 24 d
[15–38], p = 0.001) were significantly shorter in patients
with prolonged empirical antifungal treatment compared
with those with non prolonged empirical antifungal
treatment. However, ICU mortality was similar in the
two groups (46 versus 52%, p = 0.62).
Discussion
Our results suggest that empirical antifungal treatment
is used in about one third of ICU patients hospitalized
for more than 48 h, during 48% of their ICU stay.
Chemotherapy, and suspicion of infection at ICU admis-
sion were independently associated with prolonged em-
pirical antifungal treatment. Although duration of
mechanical ventilation and ICU stay were significantly
shorter in patients with prolonged empirical antifungal
treatment compared with those with no prolonged em-
pirical antifungal treatment, no significant impact of
prolonged empirical antifungal treatment was found on
ICU mortality.
To the best of our knowledge, our study is the first to
report on the incidence of prolonged use of empirical
antifungal treatment. Empirical antifungal treatment was
used in a large percentage (27%) of ICU patients, during
a large percentage (48%) of their ICU stay. A recent
Spanish multicenter study [9] analyzed 8240 antifungal
prescriptions during a 5 year-period. An increase in anti-
fungal use was reported to the year 2008, with a subse-
quent stabilization. The median duration of antifungal
treatment was 8 days, which is in line with our results.
However, no information was provided on empirical an-
tifungal use, or on duration of ICU stay. Another recent
one-day cross sectional multicenter study was performed
to determine the incidence of ICU patients without doc-
umented invasive fungal disease who receive systematic
antifungal treatment [6]. Among the 2047 included pa-
tients, 5.2% received antifungal treatment without con-
firmed invasive fungal disease. At least two reasons
could explain the lower rate of empirical antifungal use
found in this study compared with ours. First, this study
was a one day study. Therefore, antifungals stopped be-
fore, or started after the study’s day were not taken into
account. Second, patients with short duration (<48H) of
ICU stay were not excluded from that study. These pa-
tients rarely receive antifungal treatment.
Chemotherapy, and suspicion of infection at ICU ad-
mission were identified as independent risk factors for
Table 1 Risk factors for prolonged empirical antifungal treatment at ICU admission
Patient characteristics Prolonged empirical antifungal treatment p value
Yes n = 77 No n = 76
Age, years, mean ± SD 55 ± 14 60 ± 15 0.429
Male 42 (54) 49 (64) 0.277
SAPS II 54 (35, 71) 52 (37, 73) 0.518
LOD score 7 (4,10) 7.5 (4,11) 0.423
Location before ICU admission 0.963
Other wards 60 (78) 58 (76)
Other ICUs 7 (9) 7 (9)
Home 10 (13) 11 (14)
Recent hospitalization 34 (44) 22 (28) 0.058
Category of admission 0.500
Medical 58 (75) 51 (67)
Surgical 18 (23) 23 (30)
Trauma 1 (1) 2 (2)
Comorbidities
Diabetes 14 (18) 19 (25) 0.305
Chronic heart failure 15 (19) 9 (12) 0.192
COPD 15 (19) 16 (21) 0.809
Cirrhosis 4 (5) 4 (5) >0.999
Chronic dialysis 6 (7) 5 (6) 0.771
Immunosuppression
Neutropenia 14 (18) 7 (9) 0.111
Chemotherapy 22 (28) 8 (10) 0.005*
Corticosteroids 21 (27.3) 9 (12) 0.017*
McCabe score 0.137
Non fatal disease 24 (31) 34 (44)
Ultimately fatal disease 23 (29) 14 (18)
Rapidly fatal disease 30 (38) 28 (36)
Causes for ICU admission**
Septic shock 42 (54) 36 (47) 0.374
Acute exacerbation of COPD 21 (27) 14 (18) 0.192
ARDS 13 (16) 20 (26) 0.156
CAP 11 (14) 14 (18) 0.489
HAP 24 (31) 12 (15) 0.024*
Congestive heart failure 5 (6) 2 (2) 0.442
Poisoning 2 (2) 8 (10) 0.056
Neurologic failure 2 (2) 6 (7) 0.167
Infection on admission 72 (93) 58 (76) 0.002*
Prior antibiotic treatment 45 (58) 33 (43) 0.063
Prior antifungal treatment 25 (32.5) 10 (13) 0.004*
*OR (95% CI) 3.3 (1.3-8.1), 2.7 (1.1-6.4), 2.4 (1.1-5.2), 4.4 (1.5-12.7), 3.1 (1.4-7.1); respectively.
**Several patients had more than one cause for ICU admission.
Data are n (%), or median (25th, 75th IQR), unless otherwise specified.
SAPS, simplified acute physiology score; LOD, logistic organ dysfunction; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; ARDS, acute
respiratory distress syndrome; CAP, community acquired pneumonia; HAP, hospital acquired pneumonia.
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Table 2 Patient characteristics during ICU stay
Patient characteristics Prolonged empirical antifungal treatment p value
Yes n = 77 No n = 76
Multifocal fungal colonization 24 (31) 35 (46) 0.076
Antimicrobial treatment 73 (94) 70 (93) 0.744
Mechanical ventilation 59 (76) 67 (88) 0.059
Duration of mechanical ventilation, d 12.5 (4, 25) 20 (0, 36) 0.007
Central venous catheter 69 (89) 71 (93) 0.396
Duration of central venous catheter use, d 13 (4, 20) 18 (10, 25) 0.015
Arterial catheter 62 (81) 71 (93) 0.025*
Duration of arterial catheter use, d 8 (3, 15) 13 (10, 20) 0.002
Dialysis 30 (39) 28 (37) 0.97
Parenteral nutrition 26 (33) 29 (38) 0.571
Duration of antifungal treatment, d 9 (4, 19) 6 (2, 11) 0.003
Percentage of days in the ICU with antifungals 80 (65, 100) 25 (13, 35) <0.001
Length of ICU stay, d 14 (5, 27) 22 (14, 39) 0.001
ICU mortality 36 (46) 39 (52) 0.518
*OR (95% CI) 0.3 (0.1-0.9).
Data are n (%), or median (25th, 75th IQR).
ICU, intensive care unit.
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reflect patients with increased risk for invasive fungal
disease. Previous studies reported that immunosup-
pressed patients, and those with other infections and
prior antibiotic treatment are at higher risk for invasive
fungal disease [10-13]. However, none of these factors is
modifiable.
There is no consensual definition for prolonged anti-
fungal treatment, probably because this duration could
be very different according to ICU population and local
protocols. In order to adjust for duration of ICU stay,
and to take into account the number of days in the ICU
without antifungals, we used the median of percentage
of days in the ICU with antifungals to define prolonged
antifungal treatment. This definition is probably more
accurate than total duration of antifungal treatment, or
days in the ICU without antifungals. For example, two
patients who receive the same duration of antifungal
treatment (7 days) in the ICU could have a percentage
of days in the ICU with antifungals of 100% and 50%, if
they are discharged at day 7, and day 14; respectively.
This adjustment was already used for antimicrobials in
previous studies [14,15].
Duration of mechanical ventilation and ICU stay were
significantly shorter in patients with prolonged empirical
antifungal treatment compared with those with no pro-
longed empirical antifungal treatment. This result could
be explained by the definition we used for prolonged an-
tifungal treatment. Based on this definition, the shorter
duration of ICU stay, the higher percentage of days with
empirical antifungal treatment. However, no significantimpact of prolonged empirical antifungal treatment was
found on ICU mortality, suggesting that prolonged em-
pirical antifungal treatment is probably not justified in
this population. Further, percentage of patients with ar-
terial catheter, and those under mechanical ventilation
are higher in patients with no prolonged empirical anti-
fungal treatment compared with those with prolonged
antifungal treatment. The explanation for these findings
is probably the longer duration of ICU stay in patients
with no prolonged duration of antifungal treatment. Pre-
vious studies clearly showed that patients with longer
duration of ICU stay receive more invasive procedures,
for longer period of time [16,17].
Potential explanations for the high percentage of pa-
tients with prolonged antifungal treatment in our ICU
include the difficult diagnosis of invasive fungal disease
in ICU patients [18], and the absence of recommenda-
tions on optimal duration of treatment and de-escalation
in this population [5]. Prolonged use of antifungals is as-
sociated with high hospital cost [19], and increased risk
for fungal resistance [7]. Further studies should deter-
mine the impact of clinical, and biological markers use
on duration of empirical antifungal treatment, and pa-
tient outcomes. For example, the use of PCR [20,21],
galactomannan [22], and biomarkers for invasive fungal
disease, such as mannan, anti-mannan [9,23,24], and β-
D-glucan [25-29], could be helpful for reducing duration
of empirical antifungal treatment. In our ICU, galacto-
mannan, and biomarkers for invasive fungal disease are
available, and used by physicians. However, no clear rec-
ommendation is available on how to use these markers
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critically ill patients.
Our study has some limitations, including the retro-
spective observational design, and the single center de-
sign. Therefore, other large prospective multicenter
studies are needed to confirm our results. Further, no in-
formation was collected on corticosteroid treatment dur-
ing ICU stay. In fact, corticosteroids treatment in the
ICU might reflect refractory septic shock. No significant
difference was found in percentage of patients with sep-
tic shock at ICU admission between patients with pro-
longed empirical antifungal use and those with no
prolonged empirical treatment. However, no information
was collected on septic shock occurring during ICU stay.
In addition, as no information was available on appropri-
ateness of antibiotic treatment in patients with infection,
we could not adjust for for this factor in mortality ana-
lysis. Finally, as explained above, the prolonged duration
of mechanical ventilation and ICU stay in patients who
had no prolonged duration of antifungal treatment is
probably due to the definition we used for this condi-
tion. However, the possibility of beneficial effects of anti-
fungal treatment on duration of mechanical ventilation
and ICU stay could not be ruled out. Further random-
ized controlled studies are needed to determine the im-
pact of duration of empirical antifungal treatment on
outcome of critically ill patients.
Conclusion
Empirical antifungal treatment was used in a large pro-
portion of study patients. Chemotherapy, and suspicion
of infection at ICU admission were independently asso-
ciated with prolonged empirical antifungal treatment.
No significant impact of prolonged empirical antifungal
treatment was found on ICU mortality.
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